Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Dobbins, MD, PhD
Melinta Therapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Fountain Valley, California, United States
- Facility name not stated
San Dimas, California, United States
- Facility name not stated
Sylmar, California, United States
- Facility name not stated
Torrance, California, United States
- Facility name not stated
Tamarac, Florida, United States
- Facility name not stated
Springfield, Illinois, United States
- Facility name not stated
Louisville, Kentucky, United States
- Facility name not stated
Baltimore, Maryland, United States
- Facility name not stated
Boston, Massachusetts, United States
- Facility name not stated
Detroit, Michigan, United States
- Facility name not stated
Butte, Montana, United States
- Facility name not stated
Somers Point, New Jersey, United States
- Facility name not stated
Charlotte, North Carolina, United States
- Facility name not stated
Cincinnati, Ohio, United States
- Facility name not stated
Cleveland, Ohio, United States
- Facility name not stated
Haverford, Pennsylvania, United States
- Facility name not stated
Malvern, Pennsylvania, United States
- Facility name not stated
Philadelphia, Pennsylvania, United States
- Facility name not stated
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2015
- Primary completion
- 17 Oct 2017
- Completion
- 21 Feb 2019
- Last update posted
- 30 Jan 2020
- Registered enrollment
- 30
- Registry id
- NCT02569541
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.